Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease
A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia (CLL), Prolymphocytic Leukemia (PLL), or Small Lymphocytic Lymphoma (SLL)
Sponsor: Cambridge Antibody Technology
This PHASE1 trial investigates Leukemia and is currently ongoing. Cambridge Antibody Technology leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE1
First recorded
Mar 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cambridge Antibody Technology
For direct contact, visit the study record on ClinicalTrials.gov .